These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 35222371)

  • 1. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
    Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
    Front Immunol; 2022; 13():783495. PubMed ID: 35222371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An
    Han Y; Wong FC; Wang D; Kahlert C
    Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature.
    Shen L; Huang H; Li J; Chen W; Yao Y; Hu J; Zhou J; Huang F; Ni C
    Front Immunol; 2023; 14():1199465. PubMed ID: 37469520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma.
    Jiang A; Chen X; Zheng H; Liu N; Ding Q; Li Y; Fan C; Fu X; Liang X; Tian T; Ruan Z; Yao Y
    Int J Med Sci; 2022; 19(4):711-728. PubMed ID: 35582412
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma.
    Tian Q; Zhou Y; Zhu L; Gao H; Yang J
    Front Cell Dev Biol; 2021; 9():684259. PubMed ID: 34307361
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis.
    Jiang Y; Hammad B; Huang H; Zhang C; Xiao B; Liu L; Liu Q; Liang H; Zhao Z; Gao Y
    Transl Lung Cancer Res; 2024 Jun; 13(6):1277-1295. PubMed ID: 38973963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
    Wang H; Lu X; Chen J
    BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel anoikis-related gene signature to predict the prognosis, immune infiltration, and therapeutic outcome of lung adenocarcinoma.
    Wang Y; Xie C; Su Y
    J Thorac Dis; 2023 Mar; 15(3):1335-1352. PubMed ID: 37065587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer.
    Zhang Z; Fang T; Lv Y
    Front Genet; 2022; 13():934830. PubMed ID: 36171887
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
    Wang X; Jing H; Li H
    Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
    Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
    J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer.
    Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H
    BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.